July 25, 2021 08:45 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
TMC nominates former IAS and Modi critic Jawhar Sircar to Rajya Sabha | Tokyo Olympics: Weightlifter Mirabai Chanu wins silver | Kashmir: Two militants killed by security forces in Bandipora encounter | India records 39,097 new COVID-19 cases in past 24 hours | Bharat Biotech ends Covaxin supply agreements with Brazilian firms amid political row
Lupin receives USFDA approval for Sevelamer Hydrochloride tablets Lupin
Image Credit: UNI

Lupin receives USFDA approval for Sevelamer Hydrochloride tablets

India Blooms News Service | @indiablooms | 17 Jun 2021, 06:19 pm

Mumbai/UNI: Pharma major Lupin on Thursday said that it has received approval for its Sevelamer Hydrochloride Tablets, 400 mg and 800 mg from the United States Food and Drug Administration (USFDA) to market a generic equivalent of Renagel Tablets, 400 mg, and 800 mg of Genzyme Corporation.

The product will be manufactured at Lupin's facility in Nagpur, India.

Sevelamer Hydrochloride Tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Sevelamer Hydrochloride Tablets had an estimated annual sales of USD 80 million in the US (IQVIA MAT March 2021).